Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ADC Therapeutics SA Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 6-K Quarterly results
Docs: "6-K",
"Unaudited IFRS Condensed Consolidated Interim Financial Statements",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/20/2023 6-K Quarterly results
07/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
05/09/2023 6-K Quarterly results
Docs: "6-K",
"Unaudited IFRS Condensed Consolidated Interim Financial Statements",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update"
05/05/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Invitation to the Annual General Meeting",
"ADC Therapeutics SA Shareholder Meeting Notice",
"Annual General Meeting Proxy Card (Record Holders)",
"Annual General Meeting Proxy Card (Brokers)"
04/05/2023 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
03/30/2023 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
03/29/2023 SC TO-I/A Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
03/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/15/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "2022 Annual Report",
"2022 Annual Report"
03/15/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
03/06/2023 SC TO-I Form SC TO-I - Tender offer statement by Issuer:
02/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 6% stake in ADC THERAPEUTICS SA
02/06/2023 6-K Quarterly results
02/06/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/02/2023 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
02/02/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
02/02/2023 6-K Quarterly results
02/02/2023 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
01/09/2023 6-K Quarterly results
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer"
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference"
12/22/2022 SC 13D/A AUVEN THERAPEUTICS HOLDINGS LP reports a 23.8% stake in ADC Therapeutics SA
12/21/2022 6-K Quarterly results
12/19/2022 6-K Quarterly results
12/09/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/08/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/08/2022 6-K Quarterly results
Docs: "6-K",
"Unaudited IFRS Condensed Consolidated Interim Financial Statements",
"MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy